Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Interleukin-2 therapy for myelodysplastic syndrome: does it work?

K Ogata¹, N Yokose, T Nomura

¹Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.

Leukemia & Lymphoma

|May 1, 1995

Summary

Interleukin-2 (IL-2) shows potential for myelodysplastic syndromes (MDS). In vitro studies reveal reduced immune cell activity in high-risk MDS, suggesting IL-2 therapy may benefit specific patient groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of catechins on the mouse tumor cell adhesion to fibronectin.

Planta medica·1995

Same author

[Specific DNA recognition by Myb protein].

Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme·1995

Same author

A rapid radioimmunoassay for the measurement of antibodies to glutamic acid decarboxylase in human serum.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·1995

Same author

A new method for the relief of adult phimosis.

The Journal of urology·1995

Same author

[The glutamic acid decarboxylase (GAD) antibodies and their clinical significance].

Rinsho byori. The Japanese journal of clinical pathology·1995

Same author

Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.

British journal of haematology·1995

Area of Science:

Hematology
Immunology
Oncology

Background:

Myelodysplastic syndromes (MDS) are clonal hematologic disorders often associated with immune system dysfunction.
Interleukin-2 (IL-2) has shown therapeutic promise in other hematologic malignancies, but its role in MDS remains uncertain.

Purpose of the Study:

To investigate the in vitro effects of IL-2 on myelodysplastic syndromes (MDS).
To evaluate the potential of IL-2 therapy in different MDS subtypes based on immune cell responses.

Main Methods:

Assessed IL-2's effect on blast proliferation in MDS samples.
Measured the cytotoxicity of IL-2-induced lymphokine-activated killer (LAK) cells against MDS blasts.
Analyzed the correlation between soluble IL-2 receptor (sIL-2R) levels and immune cell function (NK and CD8+ T cells).

More Related Videos

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Jul 12, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Main Results:

IL-2 did not significantly increase blast proliferation in most MDS cases.
LAK cell cytotoxicity was reduced in high-risk MDS but preserved in low-risk MDS.
Reduced LAK cell function in MDS was partly attributed to fewer natural killer (NK) cells; high sIL-2R levels correlated with impaired NK and CD8+ T cell function.

Conclusions:

The response to IL-2 therapy in MDS is heterogeneous.
Patients with low-risk MDS and/or low blood sIL-2R levels may be more likely to benefit from IL-2 treatment.
Further clinical trials are essential to confirm the efficacy of IL-2 in treating MDS.